David D Griffith

Address:

10906 W Blake Cir, Wichita, KS 67209

VIN:

1HGFA16887L063464

Make:

HONDA

Model:

CIVIC

Year:

2007

US Patent:

6399631, Jun 4, 2002

Filed:

Jul 21, 2000

Appl. No.:

09/620315

Inventors:

Richard L. Elliott - East Lyme CT
David A. Griffith - Old Saybrook CT
Marlys Hammond - Salem CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 314375

US Classification:

514314, 514323, 514411, 546175, 546200, 548444

Abstract:

Carbazoles of the formula which are effective in treating conditions associated with neuropeptide Y-5 neurotransmission.

US Patent:

6429313, Aug 6, 2002

Filed:

Mar 30, 2001

Appl. No.:

09/822109

Inventors:

Philip Albert Carpino - Groton CT
David Andrew Griffith - Old Saybrook CT
Bruce Allen Lefker - Gales Ferry CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D48704

US Classification:

544350

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

US Patent:

6432945, Aug 13, 2002

Filed:

Mar 30, 2001

Appl. No.:

09/822095

Inventors:

Philip Albert Carpino - Groton CT
David Andrew Griffith - Old Saybrook CT
Bruce Allen Lefker - Gales Ferry CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31542

US Classification:

5142228, 514 19, 5142265, 514249, 544 10, 544 47, 544 48, 544350

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

US Patent:

6433171, Aug 13, 2002

Filed:

Mar 30, 2001

Appl. No.:

09/823051

Inventors:

Philip Albert Carpino - Groton CT
David Andrew Griffith - Old Saybrook CT
Bruce Allen Lefker - Gales Ferry CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D48704

US Classification:

544350

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or fraility, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

US Patent:

6525047, Feb 25, 2003

Filed:

Mar 30, 2001

Appl. No.:

09/822738

Inventors:

Philip Albert Carpino - Groton CT
David Andrew Griffith - Old Saybrook CT
Bruce Allen Lefker - Gales Ferry CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31517

US Classification:

5142305, 514 19, 514249, 544 91, 544279, 544349, 544350

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B- HT920.

US Patent:

RE38524, Jun 1, 2004

Filed:

Oct 15, 2002

Appl. No.:

10/270816

Inventors:

Philip Albert Carpino - Groton CT
David Andrew Griffith - Old Saybrook CT
Bruce Allen Lefker - Gales Ferry CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31517

US Classification:

514249, 51425304, 544349, 544350

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

US Patent:

6924280, Aug 2, 2005

Filed:

Feb 21, 2003

Appl. No.:

10/371330

Inventors:

Philip Albert Carpino - Groton CT, US
David Andrew Griffith - Old Saybrook CT, US
Bruce Allen Lefker - Gales Ferry CT, US

Assignee:

Pfizer Inc. - Groton CT

International Classification:

A61K031/55
C07D287/04

US Classification:

51421109, 5142111, 514299, 514300, 514301, 514302, 514303, 514412, 540593, 546112, 546114, 546115, 546118, 546122, 548452, 548453

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, conjugated estrogens, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

US Patent:

6951850, Oct 4, 2005

Filed:

Feb 21, 2003

Appl. No.:

10/371953

Inventors:

Philip Albert Carpino - Groton CT, US
David Andrew Griffith - Old Saybrook CT, US
Bruce Allen Lefker - Gales Ferry CT, US

Assignee:

Pfizer, Inc. - Groton CT

International Classification:

A61K031/519
C07D471/04

US Classification:

5142111, 5142641, 5142651, 540476, 540578, 544279, 544280

Abstract:

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, conjugated estrogens, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.